FVIII-containing platelets modulate immune responses and attenuate inhibitor development in hemophilia A mice
FVIII-engineered platelets and platelet-derived products are potent immune modulators. These strategies offer novel and translatable approaches to both restore hemostasis and prevent or eradicate inhibitors in HA.
Authors
- Weiqing Jing (ORCID: https://orcid.org/0000-0002-3008-9873)
- Jocelyn A. Schroeder (ORCID: https://orcid.org/0000-0001-8953-5201)
- Yingyu Chen (ORCID: https://orcid.org/0000-0002-1559-5698)
- Qizhen Shi
- Feng Xue
- Heyu Ni
- Saurabh Kumar
Institutions
- Children's Hospital of Wisconsin (US)
- Fujian Medical University (CN)
- St. Michael's Hospital (CA)
- Versiti Blood Center of Wisconsin (US)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Canadian Blood Services (CA)
Publication Details
- Journal
- Haematologica
- Published
- 2026-02-12
- DOI
- https://doi.org/10.3324/haematol.2025.289331
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Midwest Athletes Against Childhood Cancer
- National Natural Science Foundation of China
- National Institutes of Health
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute